Fellowships, Grants, & Awards by unknown
Lung Response to Inhaled Highly Toxic
Chemicals
The purpose of this program announcement
(PA) is to investigate acute mucosal irritation
in the upper and lower respiratory tract occur-
ring after aerosol exposure to toxic chemicals
with the goals to: 1) minimize initial injury
promptly, 2) retard and ameliorate progressive
mucosal irritation or inflammation, and 3)
offer prophylaxis against pulmonary edema, if
created by acute lung injury.
The National Heart, Lung, and Blood
Institute (NHLBI) and the NIEHS are con-
cerned about the U.S. population’s potential
inhalational exposure to aerosolized harmful
chemicals, possibly liberated as part of bioter-
rorism attacks against assembled groups of the
civilian populace. Therefore, research is
needed on how humans and relevant animal
models respond to inhaled toxic chemicals.
The goals of this PA are to develop better bio-
protective therapies and to minimize respira-
tory injury and illness.
Many volatile toxic chemicals are pro-
duced and utilized in industry. Some of these
are considered hazardous when they are
inhaled in ambient air, introduced into food
and water supplies, or make contact with body
skin surfaces. Among toxic industrial materials
that are considered highly hazardous are
ammonia, chlorine, formaldehyde, hydrogen
cyanine, fuming nitric acid, phosgene, and
sulfur dioxide.
From a pulmonary perspective, inhalation
exposure to some of these highly hazardous
and irritative chemicals induces initial chok-
ing, inability to breathe deeply, and excessive
output of secretions in the nose and throat
from acute irritation. Other chemicals that
have neurological effects—including such
nerve agents as sarin, certain organophos-
phate-based pesticides, soman, and others—
enter the body through absorption from the
airways.
The NHLBI has a limited portfolio of
existing research applicable to the respiratory
exposures discussed. This PA will stimulate
and build research against airborne chemical
threats that affect the upper and lower respira-
tory tract, and will suggest potential therapy
to prevent or limit development of pulmonary
edema, which is a major complication of air-
way chemical irritation. Examples of research
topics that are of interest include the follow-
ing: 1) investigating mechanisms of chemical
injury (including minimal threshold levels to
establish injury) and subsequent effects at a
cellular and molecular level causing airway
inflammation or hypersensitivity; 2) identify-
ing host responses to initial or immediate
effects, and to long-term low-level exposure
effects; 3) assessing systematic amount or dose
of chemical absorbed from the airways; 4)
developing preexposure preventive treatment
or early use of antidotes; and 5) devising ther-
apeutic strategies, especially if acute alveolar
lung injury occurs and pulmonary edema
ensues; specific therapies to prevent onset of
pulmonary edema are sought. Development of
physical protection (including facial masks
and respirators) or environmental detectors for
documenting exposure are not within the
purview of this announcement.
The NIEHS encourages applications to
study chemical exposures relating to civilian
terrorism attack, industrial sabotage, or large-
scale accidental exposure to toxic chemicals.
Applications should focus on research that will
develop or support development of treatment
strategies that prevent or minimize respiratory
track injury following exposure or that maxi-
mize repair of injured tissue. To be considered
responsive to the NIEHS, the chemical expo-
sure should be acute.
Multiple routes of chemical exposure (res-
piratory tract, skin, eye, digestive tract) are
acceptable if injury resulting from the expo-
sure is specific to the lung. Use of animal
models and appropriate human biological
specimens is encouraged. Examples of research
topics for the NIEHS include but are not lim-
ited to the following: 1) the relationship
between exposure, route of exposure, and
absorbed dose to onset and magnitude of res-
piratory symptoms in a young, adult, and
senior model; 2) cellular and molecular mech-
anisms of lung injury following acute chemical
exposure, including induction of mucosal
injury, pulmonary inflammation, acute alveo-
lar injury, and pulmonary edema; 3) cellular
and molecular mechanisms of lung tissue
repair following acute chemical-induced lung
injury; 4) development of postexposure strate-
gies that prevent or minimize lung injury,
including early use of antidotes; and 5) devel-
opment of therapeutic strategies that promote
lung tissue repair and that prevent or treat
pulmonary edema.
This funding opportunity will use the
NIH R01 award mechanism. As an applicant,
you will be solely responsible for planning,
directing, and executing the proposed project.
This funding opportunity uses just-in-time
concepts. It also uses the modular as well as
the nonmodular budget formats (see
http://grants.nih.gov/grants/funding/modu-
lar/modular.htm). Specifically, if you are sub-
mitting an application with direct costs in
each year of $250,000 or less, use the modular
budget format described in the PHS 398
application instructions. Otherwise, follow the
instructions for nonmodular research grant
applications.
Applications must be prepared using the
most current PHS 398 research grant applica-
tion instructions and forms. The PHS 398
application instructions are available at
http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. For fur-
ther assistance contact GrantsInfo at 301-435-
0714 or by e-mailing GrantsInfo@nih.gov.
Applications must have a Dun & Bradstreet
Data Universal Numbering System (DUNS)
number as the universal identifier when apply-
ing for federal grants or cooperative agree-
ments. This number can be obtained by
calling 1-866-705-5711 or through the web-
site at http://www.dnb.com/us/.
Applications must be mailed on or before
the receipt date described at http://grants.nih.
gov/grants/funding/submissionschedule.htm.
The complete version of this PA is available
online at http://grants.nih.gov/grants/guide/
pa-files/PA-05-058.html.
Contact: Herbert Y. Reynolds, Division of
Lung Diseases, NHLBI, 6701 Rockledge Dr,
Two Rockledge Ctr, Ste 10018, MSC 7952,
Bethesda, MD 20892 USA, 301-435-0218,
fax: 301-480-3557, e-mail: Reynoldh@
nhlbi.nih.gov; Sally S. Tinkle, Cellular, Organ
and Systems Pathobiology Branch, Division of
Extramural Research and Training, NIEHS,
111 TW Alexander Dr, PO Box 12233, MD
EC-23, Research Triangle Park, NC 27709
USA, 919-541-5327, fax: 919-541-5064, e-
mail: tinkle@niehs.nih.gov. Reference PA No.
PA-05-058 
In Utero Exposure to Bioactive Food
Components and Mammary Cancer Risk
In utero exposures are important determinants
of some cancers occurring in children and
young adults. For example, exposure to ioniz-
ing radiation in utero promotes childhood
leukemia, and maternal use of diethylstilbe-
strol during pregnancy has been linked to
clear-cell adenocarcinoma of the vagina in
these women’s daughters. In addition, mater-
nal diets—specifically the consumption of
vegetables, fruits and protein—are linked to
decreased risk of childhood leukemia.
The prenatal period is critical in the devel-
opment of the mammary gland. During this
time, the mammary gland is in a largely undif-
ferentiated state, making it particularly vulner-
able to a host of environmental forces.
Inappropriate nutritional status or exposure to
environmental chemicals and the accompanied
alteration in growth and endocrine homeosta-
sis may permanently change the fetus’s struc-
ture, physiology, and metabolism, thereby
predisposing it to various diseases in later life
including mammary cancer.
Epidemiological studies suggest that alter-
ing the intrauterine nutritional status can
increase mammary cancer risk. Failure of the
materno-placental supply line to satisfy fetal
nutrient requirements can result in a range of
fetal adaptations and developmental changes.
Birth weight is a gross surrogate marker for
shifts in a host of metabolic processes. Many,
but not all, studies reveal a positive relation-
ship between increased birth weight and breast
cancer risk. Likewise, other indicators of fetal
size such as increased placental weight and
birth length are positively correlated with
breast cancer risk in the offspring. Recent
studies suggest that birth weight is indepen-
dent from neonatal growth patterns and the
timing of puberty as a risk factor for breast
cancer.
In addition to nutrition, the hormonal envi-
ronment in the womb may play an important
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cancer in female offspring. A reduction in cir-
culating levels of estrogens and insulin-like
growth factor 1 (IGF-1) and/or elevated levels
of progesterone, androgens, human chorionic
gonadotrophin, IGF-1 binding proteins 1 and
3, cortisol, and insulin have been associated
with reduced risk. Such hormonal and growth
factor changes are observed during preeclamp-
sia. Maternal preeclampsia has been associated
with a reduction in the female offspring’s later
risk for breast cancer after adjustment for a
variety of potential confounders.
Proliferation of primitive ductal structures
in the newborn breast leads to branching and
terminal end buds (TEBs). The expansion of
TEBs represents an opportunity for malignant
transformation because they contain pluripo-
tent mammary stem cells. In fact, in utero
exposures that bring about an increase in
TEBs coincide with increased mammary car-
cinogenesis. Evidence exists that providing
maternal diets that contain elevated amounts
of n-6 polyunsaturated fatty acids (PUFAs)
and genistein not only increased TEBs but
also reduced the differentiation of TEBs to
lobuloalveolar units. These diets also increased
subsequent chemically induced mammary can-
cer in the offspring. In addition, prenatal
exposures to environmental agents such as
bisphenol A or dioxin results in alteration in
the development of the mammary gland that
may predispose to the development of cancers
later in life. Some of this response may relate
to changes in hormonal and growth factor sta-
tus, including status of estrogen and IGF-1.
Greater estrogen exposure throughout a
woman’s life has been identified as a major
risk factor for the development of breast can-
cer. In utero exposures to the mammary gland
can achieve concentrations 10–100 times the
estrogen levels occurring later in life. Dietary
factors, such as genistein and fat, that influ-
ence estrogen exposure to the fetus are related
to subsequent cancer risk in several model sys-
tems. However, the response may not be
totally explained by estradiol, because diets
rich in n-3 fatty acids, when fed to pregnant
rats, elevate this hormone but reduce mam-
mary cancer incidence in the offspring.
It is possible that intrauterine exposure to
other hormones or environmental hormone
mimics or antagonists may also affect breast
cancer susceptibility. Androgen exposure in
utero may confer long-term protection against
breast cancer by antagonizing the effects of
estrogens on fetal breast ductal development.
Dietary fatty acids, phytoestrogens, alcohol,
and lycopene are among the various bioactive
food components reported to influence andro-
gen concentrations. Environmental agents
with estrogenic agonist or antagonist activity
may also alter gene expression during develop-
ment, which may lead to functional deficits
later in life that predispose one to cancer
development. Thus there is the need for stud-
ies focusing on uncovering the mechanisms
responsible for the protective and detrimental
effects on breast cancer risk of exposure to
bioactive food components and other environ-
mental agents in utero. These studies should
attempt to more comprehensively address the
changes in all potentially relevant pregnancy
hormones and growth factors.
Although the effects of in utero exposure
to dietary components have been inadequately
examined, considerable evidence exists for
their ability to modify IGF-1 concentrations
and mammary cancer susceptibility postna-
tally. Postnatal caloric restriction decreases
IGF-1 and decreases mammary tumor growth
and metastases. Furthermore, postnatal soy
phytochemicals combined with green tea syn-
ergistically inhibited mammary tumor growth
and depressed serum IGF-1 levels in mice.
Future studies are warranted to determine
whether in utero exposure to dietary manipula-
tions that modulate IGF-1 expression will
influence subsequent breast cancer risk.
Maternal nutritional status can also alter
the epigenetic state of the fetal genome and
imprint gene expression levels with lifelong
consequences. Loss of imprinting is the silenc-
ing of active imprinted genes or the activation
of silent imprinted genes, and is one of the
most common epigenetic changes associated
with the development of a wide variety of
tumors. Several lines of evidence support the
relationship between maternal nutrition and
epigenetic changes in their offspring.
Epigenetic changes may provide a molecular
mechanism for the impact of maternal nutri-
tion or environmental chemical exposures on
postnatal disease susceptibility and deserves
future research.
Investigators may choose from the full
range of preclinical approaches. The use of
genetically engineered animal models includ-
ing transgenic or knockouts, such as those
available through the Mouse Models of
Human Cancer Consortium (MMHCC,
http://emice.nci.nih.gov/), is encouraged.
Studies that apply new high-throughput
genomic, epigenomic, proteomic, and metab-
olomic technologies to determine how dietary
and/or environmental chemical exposures in
utero influence adult breast cancer susceptibil-
ity are encouraged.
This funding opportunity will use the
NIH investigator-initiated research project
grants (R01) and exploratory/developmental
(R21) award mechanisms. Illustrative exam-
ples for the development of R01 or R21 appli-
cations include, but are not limited to, the
following: 1) utilization of transgenic and
knockout mouse models of human mammary
cancer to identify molecular sites of action of
bioactive food components in cancer preven-
tion; 2) examination of the role of moderate
caloric restriction in utero on hormone con-
centrations and mammary cancer prevention;
3) evaluation of synergistic effects of exposure
to bioactive food components in utero and
subsequent mammary cancer risk; 4) evaluation
of imprinted genes after exposure to bioactive
food components in utero and subsequent
mammary cancer risk; 5) examination of the
role of in utero exposures to environmental
agents such at mycotoxins, heterocylic amines,
bisphenol A, phthalates, and other agents with
endocrine-like agonist or antagonist activity
and subsequent mammary cancer risk; and 6)
examination of the interaction of in utero
exposures to bioactive food components and
exposures to environmental agents in the etiol-
ogy of breast cancer later in life.
No set-aside funds are available for this
funding opportunity. Applicants may request
up to 5 years of support for R01 awards with
costs appropriately tailored to the proposed
work. No limit is set on the costs requested by
R01 applicants. An R21 applicant may request
a project period of up to 2 years with a com-
bined budget for direct costs of up to
$275,000 for the 2-year period. Normally, no
more than $200,000 may be requested in any
single year. 
Because the nature and scope of the pro-
posed research will vary from application to
application, it is anticipated that the size and
duration of each award will also vary.
Although the financial plans of the involved
institutes and centers provide support for this
program, awards pursuant to this funding
opportunity are contingent upon the availabil-
ity of funds and the receipt of a sufficient
number of meritorious applications.
Applications must be prepared using the
most current PHS 398 research grant applica-
tion instructions and forms. The PHS 398
application instructions are available at
http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. For fur-
ther assistance contact GrantsInfo at 301-435-
0714 or by e-mailing GrantsInfo@nih.gov.
Applications must have a Dun & Bradstreet
Data Universal Numbering System (DUNS)
number as the universal identifier when apply-
ing for federal grants or cooperative agree-
ments. This number can be obtained by
calling 1-866-705-5711 or through the web-
site at http://www.dnb.com/us/.
Applications must be received by the
dates listed at http://grants.nih.gov/grants/
funding/submissionschedule.htm. The com-
plete version of this PA is available at http://
grants.nih.gov/grants/guide/pa-files/
PA-05-059.html. 
Contact: Cindy D. Davis, Division of
Cancer Prevention, National Cancer Institute,
6130 Executive Blvd, EPN Rm 3159, MSC
7328, Bethesda, MD 20892-7328 USA, 301-
594-9692, fax: 301-480-3925, e-mail: davisci@
mail.nih.gov; Mary Frances Picciano, Office of
Dietary Supplements, 6100 Executive Blvd,
Rm 3B01, Bethesda, MD 20892-7517 USA,
301-435-3608, e-mail: PiccianM@mail.nih.
gov; Jerry Heindel, Cellular, Organs, and
Systems Pathobiology Branch, Division of
Extramural Research and Training, NIEHS,
PO Box 12233, Research Triangle Park, NC,
27709 USA, 919-541-0781, fax: 919-541-
5064, e-mail: heindelj@niehs.nih.gov. Ref-
erence PA No. PA-05-059
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